One of these nonrandomized single-centre phase II studies evaluated the combination of docetaxel and trastuzumab for patients with metastatic or unresectable ductal carcinoma with HER-2 overexpression, with a response rate of 70% [56]. The gene discussed is ERBB2; the disease is breast ductal adenocarcinoma.